Figure S6


A
iPSCs fate in serum
Obox6+
Log odds (iPSCs vs non-iPSCs)
Day
B
Serum
Bright field
Oct4–EGFP
Zfp42
Obox6
Control
C
Percentage of Oct4–EGFP+ cells (%)
Zfp42
Obox6
Control
D
2nd MEFs
Percentage of Oct4–EGFP+ cells (%)
1st exp. (2i)
2nd exp. (2i)
3rd exp. (2i)
4th exp. (2i)
4th exp. (serum)
5th exp. (2i)
5th exp. (serum)
E
Primary MEFs
# of Oct4–EGFP+ colonies
1st exp. (2i)
2nd exp. (2i)
F
Primary MEFs
# of Oct4–EGFP+ colonies
1st exp. (serum)
2nd exp. (serum)
Zfp42
Obox6
Control
G
GDF9
Control
# of Oct4–EGF+ colonies
1st Exp (0.1μg/ml)
1st Exp (0.5μg/ml)
1st Exp (1μg/ml)
2nd Exp (1μg/ml)
3rd Exp (1μg/ml)
4th Exp (1μg/ml)
H
Day 15, GDF9 single-cell RNA-Seq
iPSCs
Trophoblast
Neural
Epithelial + other
Stromal
tSNE 2
tSNE 1
I
Day 15, GDF9 single-cell RNA-Seq
Control
GDF9 (1μg/ml)
Fraction of cells
iPSCs
Neural
Trophoblast
Stromal
Epithelial + other
Experiment